DSM 421 - Medicines for Malaria Venture/Takeda

Drug Profile

DSM 421 - Medicines for Malaria Venture/Takeda

Alternative Names: DSM-421

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator Takeda
  • Developer Medicines for Malaria Venture; Takeda
  • Class Antimalarials; Pyrimidines; Triazoles
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Malaria

Most Recent Events

  • 30 Mar 2017 Phase-I clinical trials in Malaria in Japan (PO)
  • 04 Oct 2016 Preclinical trials in Malaria in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top